# **Rajthanee Hospital**

Rajthanee Hospital Public Company Limited

### Tue, Nov 12, 2024

Bloomberg

Reuters



## 3Q24: Beat on revenue and tax income

RJH reported high 3Q24 net profit of Bt214mn, up 77% YoY and 80% QoQ, beating market estimates by 39% from high revenue, largely from SC services, and tax income. While we have upgraded earnings, we continue to expect a short-term earnings hiccup from the initial cost burden from the new facility in 4Q24 and 2025. We thus maintain Neutral on RJH with an end-2025 DCF TP of Bt29/share.

**3Q24: Beat estimates on strong revenue plus tax income.** RJH reported 3Q24 net profit of Bt214mn, up 77% YoY and 80% QoQ, with strong revenue and tax income leading it to beat market estimates by 39%.

### **Highlights:**

- Revenue was Bt794mn, up 28% YoY and 14% QoQ. By service, revenue from the social security scheme (SC, 52% of revenue) grew 52% YoY and 16% QoQ, driven by rising average revenue per insured person (up 51% YoY and 16% QoQ) reflecting more intensive cases and additional revenue from 26 chronic diseases. Revenue from IPD service (25% of revenue) grew 12% YoY and 12% QoQ and revenue from OPD service (23% of revenue) increased 10% YoY and 14% QoQ.
- EBITDA margin was 32.6% in 3Q24, up from 30.7% in 3Q23 and 27.8% in 2Q24 due to the strong revenue.
- RJH reported tax income of Bt1mn vs. tax expense of Bt30mn in 3Q23 and 2Q24 as it received tax benefit from donating medical equipment to public hospitals in the quarter.

**Earnings raised, but expect earnings to slow down in 2025.** We revised up our 2024 core earnings by 19% and 2025F by 10% to factor in the beat in 3Q24. RJH opened a new hospital, *Rajthanee Nongkhae Hospital*, in Saraburi on October 1 and we believe the initial cost burden will cause a short-term earnings hiccup and thus expect 4Q24 core earnings to be flat YoY but drop QoQ, with 2025 core earnings slipping 6% YoY in the first full year of the new investment. With this, we maintain our Neutral rating on RJH with an end-2025 TP of Bt29/share (up from end-2024 TP of Bt28/share), based on WACC at 6% and long-term growth at 2%.

**Risks.** Change in SC reimbursement, slower patient traffic and cost burden at new facilities. We see ESG risk as patient safety (S): RJH has adopted a variety of quality assurance systems to provide continuous patient care.

### **Forecasts and valuation**

I OI COUSta una Valua						
Year to 31 Dec	Unit	2022	2023	2024F	2025F	2026F
Revenue	(Btmn)	3,365	2,348	2,838	3,014	3,150
EBITDA	(Btmn)	1,478	698	837	889	976
Core profit	(Btmn)	1,029	420	563	531	580
Reported profit	(Btmn)	1,029	420	548	531	580
Core EPS	(Bt)	3.44	1.40	1.88	1.77	1.93
DPS	(Bt)	2.50	1.20	1.55	1.50	1.64
P/E, core	(x)	6.6	16.2	12.1	12.8	11.7
EPS growth, core	(%)	1.9	(59.3)	34.1	(5.7)	9.2
P/BV, core	(x)	3.0	3.3	3.0	3.0	2.8
ROE	(%)	48.0	18.0	23.0	20.6	21.6
Dividend yield	(%)	11.0	5.3	6.8	6.6	7.2
EV/EBITDA	(x)	5.1	11.1	9.5	9.3	8.6
EBITDA growth	(%)	2.9	(52.8)	19.9	6.2	9.9

Source: InnovestX Research

## **Tactical: NEUTRAL**

### (3-month)

RJH TB

RJH.BK

#### Stock data Last close (Nov 11) (Bt) 22.70 Target price (Bt) 29.00 Mkt cap (Btbn) 6.81 12-m high / low (Bt) 28.3 / 21.6 Avg. daily 6m (US\$mn) 0.11 30/6 Foreign limit / actual (%) Free float (%) 57.5 **Outstanding Short Position (%)** 0.02

Share price performance								
(%)	1M	3M	12M					
Absolute	(2.6)	1.8	(14.3)					
Relative to SET	(1.7)	(9.3)	(18.3)					

INVX core earnings vs consensus							
Earnings vs consensus	2024F	2025F					
Consensus (Bt mn)	475	463					
INVX vs Consensus (%)	18.5	14.6					

Earnings momentum	YoY	QoQ
INVX 4Q24 core earnings	Flat	Down

### 2023 Sustainability/2022 ESG Score SET ESG Ratings n.a.

Bloomberg ESG Score and Rank in t	he sector
ESG Score and Rank	n.a. n.a.
Environmental Score and Rank	n.a. n.a.
Social Score and Rank	n.a. n.a.
Governance Score and Rank	n.a. n.a.
Original OFT In a supply Descended Direction F	

Source: SET, InnovestX Research, Bloomberg Finance L.P.

### Analyst

Raweenuch Piyakriengkai Fundamental Investment Analyst on Securities (66-2) 949-1002 raweenuch.p@innovestx.co.th



### **Our view on ESG**

RJH plans to improve ESG but so far the plans are not concrete nor is the target committed. We see ESG risk as patient safety (S) and RJH has adopted a variety of quality assurance systems to provide continuous patient care.

### **ESG** Ratings and Indices

Bloomberg ESG Financial Materiality Score	n.a.		<b>CG</b> Rating	DJSI	SETESG	SET ESG Ratings
Rank in Sector	n.a.	RJH	3	No	No	No
		Source: Th	hai Institute of Direc	ctors and	SET	
Environmental Issue (E)		Social I	ssue (S)			
<ul> <li>Wastewater treatment: Wastewater from the treated until its quality meets standards before disposing to water resources outside the hose</li> <li>Hazardous material and waste management</li> </ul>	ore spitals.	that has	could be harr	nful to pation	patients' a al safety st	res to minimize risks nd staff's health. RJH affs to monitor and
measures of waste sorting, wearing persona procedures for spills of hazardous materials route maps and schedules for waste transpo	l protection, as well as	the		for Lev	el 2 Hospit	6): RJH has awarded al Accreditation (HA)

### Governance Issue (G)

- RJH has a policy to act against corruption by providing written a guideline which is specified in the document "Rules and regulations in the operation of the hospital" and communicated to the directors, executives and employees for acknowledgment and implementation.
- As of December 31, 2023, there are 9 directors, 3 of whom are independent directors, or 33.33% of the board. We view the structure is appropriate as independent directors are not less than one-third of the total members.
- The chairman is an independent director.
- Major shareholders control 24.93% of total issued and paid-up shares.

### Disclaimer

Bloomberg ESG Scores rate companies on their level of management of financially material industry-specific ESG issues. Bloomberg offers four financially material scores, for overall ESG, as well as Environmental, Social, and Governance. Values range from 0 to 10; 10 is best. To review the fully transparent methodology, see ESG Financial Materiality Score Model in Bloomberg.

### ESG Financial Materiality Score and Disclosure

	2022	2023
ESG Financial Materiality Score	—	_
Environment Financial Materiality Score	_	_
Social Financial Materiality Score	_	_
Governance Financial Materiality Score	_	_
Source: Bloomberg Finance L.P.		

### Rajthanee Hospital PLC



### Financial statement Profit and Loss Statement

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Total revenue	(Btmn)	1,771	1,855	3,118	3,365	2,348	2,838	3,014	3,150
Cost of goods sold	(Btmn)	1,213	1,262	1,684	1,848	1,618	1,884	2,020	2,086
Gross profit	(Btmn)	557	594	1,434	1,518	730	954	993	1,064
SG&A	(Btmn)	188	163	183	245	222	319	333	342
Other income	(Btmn)	131	23	27	41	45	43	45	63
Interest expense	(Btmn)	4	0	6	24	34	54	51	69
Pre-tax profit	(Btmn)	496	453	1,271	1,289	519	623	655	717
Corporate tax	(Btmn)	0	99	40	255	256	103	81	131
Equity a/c profits	(Btmn)	0	0	0	0	0	0	0	0
Minority interests	(Btmn)	(1)	(1)	(4)	(4)	4	6	6	6
Core profit	(Btmn)	396	412	1,012	1,029	420	563	531	580
Extra-ordinary items	(Btmn)	0	0	0	0	0	(15)	0	0
Net Profit	(Btmn)	396	412	1,012	1,029	420	548	531	580
EBITDA	(Btmn)	606	541	1,436	1,478	698	837	889	976
Core EPS (Bt)	(Bt)	1.32	1.37	3.37	3.44	1.40	1.88	1.77	1.93
Net EPS (Bt)	(Bt)	1.32	1.37	3.37	3.44	1.40	1.83	1.77	1.93
DPS (Bt)	(Bt)	1.10	1.00	2.70	2.50	1.20	1.55	1.50	1.64

Balance Sheet									
FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Total current assets	(Btmn)	576	441	1,203	986	828	828	1,151	1,133
Total fixed assets	(Btmn)	967	1,272	1,428	1,869	2,450	2,574	2,693	2,825
Total assets	(Btmn)	1,685	1,899	3,352	3,788	4,020	4,270	4,756	4,906
Total loans	(Btmn)	0	70	750	1,043	1,241	1,241	1,641	1,641
Total current liabilities	(Btmn)	225	340	1,298	979	930	967	993	1,005
Total long-term liabilities	(Btmn)	0	0	0	365	658	658	1,058	1,058
Total liabilities	(Btmn)	286	398	1,387	1,463	1,684	1,722	2,148	2,160
Paid-up capital	(Btmn)	300	300	278	278	278	278	278	278
Total equity	(Btmn)	1,400	1,501	1,965	2,325	2,336	2,547	2,608	2,746
BVPS (Bt)	(Bt)	4.65	4.99	6.52	7.49	6.82	7.49	7.67	8.10

### **Cash Flow Statement**

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Core Profit	(Btmn)	396	412	1,012	1,029	420	563	531	580
Depreciation and amortization	(Btmn)	106	87	159	164	145	160	183	191
Operating cash flow	(Btmn)	299	605	833	1,183	831	494	504	746
Investing cash flow	(Btmn)	185	(417)	(727)	(589)	(710)	(409)	(347)	(359)
Financing cash flow	(Btmn)	(651)	(253)	15	(532)	(23)	(351)	(69)	(442)
Net cash flow	(Btmn)	(167)	(65)	120	62	97	(267)	88	(55)

### **Key Financial Ratios**

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Gross margin	(%)	31.5	32.0	46.0	45.1	31.1	33.6	33.0	33.8
Operating margin	(%)	20.8	23.2	40.1	37.8	21.6	22.4	21.9	22.9
EBITDA margin	(%)	31.9	28.8	45.7	43.4	29.2	29.1	29.1	30.4
EBIT margin	(%)	28.2	24.4	41.0	39.0	23.5	23.9	23.4	24.9
Net profit margin	(%)	22.4	22.2	32.5	30.6	17.9	19.3	17.6	18.4
ROE	(%)	28.3	28.4	58.4	48.0	18.0	23.0	20.6	21.6
ROA	(%)	23.5	23.0	38.5	28.8	10.7	13.6	11.8	12.0
Net D/E	(x)	(0.2)	0.0	0.3	0.3	0.4	0.5	0.6	0.6
Interest coverage	(x)	139.7	2,104.1	242.8	60.4	20.8	15.6	17.6	14.2
Debt service coverage	(x)	139.7	3.9	1.0	1.1	0.6	0.7	0.7	0.8
Payout Ratio	(x)	83.4	72.7	80.0	72.7	85.8	85.0	85.0	85.0

**Main Assumptions** 

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Revenue breakdown									
Self-pay service	(%)	58.8	50.7	31.5	32.2	55.1	50.9	52.6	53.3
Social security service (SC)	(%)	41.2	41.7	25.4	26.7	44.5	48.9	47.4	46.7
Other revenues	(%)	0.0	7.5	43.2	41.1	0.3	0.2	0.0	0.0



### **Financial statement**

Profit and Loss Statement									
FY December 31	Unit	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24
Total revenue	(Btmn)	546	561	545	620	623	632	695	794
Cost of goods sold	(Btmn)	406	384	389	420	424	428	464	487
Gross profit	(Btmn)	140	176	156	199	199	204	232	306
SG&A	(Btmn)	99	48	48	53	74	56	83	90
Other income	(Btmn)	9	10	14	12	9	7	11	9
Interest expense	(Btmn)	8	7	7	8	11	12	12	14
Pre-tax profit	(Btmn)	41	132	116	149	122	143	148	211
Corporate tax	(Btmn)	7	26	22	30	25	29	30	(1)
Equity a/c profits	(Btmn)	0	0	0	0	0	0	0	0
Minority interests	(Btmn)	0	0	0	1	2	1	1	1
Core profit	(Btmn)	34	106	94	121	99	116	133	214
Extra-ordinary items	(Btmn)	0	0	0	0	0	0	(15)	0
Net Profit	(Btmn)	34	106	94	121	99	116	119	214
EBITDA	(Btmn)	86	175	159	194	171	191	196	262
Core EPS (Bt)	(Bt)	0.11	0.36	0.31	0.40	0.33	0.39	0.45	0.71
Net EPS (Bt)	(Bt)	0.11	0.36	0.31	0.40	0.33	0.39	0.40	0.71

Balance Sheet									
FY December 31	Unit	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24
Total current assets	(Btmn)	986	742	678	735	828	754	746	811
Total fixed assets	(Btmn)	1,869	1,905	1,927	2,320	2,450	2,527	2,747	2,910
Total assets	(Btmn)	3,788	3,654	3,471	3,831	4,020	3,944	4,154	4,339
Total loans	(Btmn)	1,043	792	818	1,119	1,241	1,132	1,239	1,347
Total current liabilities	(Btmn)	979	698	591	732	930	671	824	770
Total long-term liabilities	(Btmn)	365	384	496	677	658	782	794	958
Total liabilities	(Btmn)	1,463	1,200	1,184	1,515	1,684	1,545	1,718	1,819
Paid-up capital	(Btmn)	300	300	300	300	300	300	300	300
Total equity	(Btmn)	2,325	2,454	2,286	2,317	2,336	2,399	2,436	2,520
BVPS (Bt)	(Bt)	7.48	7.83	7.27	6.94	6.83	7.04	7.17	7.41

### **Cash Flow Statement**

FY December 31	Unit	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24
Core Profit	(Btmn)	34	106	94	121	99	116	133	214
Depreciation and amortization	(Btmn)	37	36	36	36	38	36	36	37
Operating cash flow	(Btmn)	468	255	186	196	193	167	169	184
Investing cash flow	(Btmn)	(188)	(143)	(61)	(348)	(158)	(156)	(245)	(195)
Financing cash flow	(Btmn)	(242)	(224)	(122)	226	97	(120)	19	21
Net cash flow	(Btmn)	38	(111)	2	74	132	(109)	(58)	10

### **Key Financial Ratios**

FY December 31	Unit	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24
Gross margin	(%)	25.6	31.5	28.7	32.1	31.9	32.3	33.3	38.6
Operating margin	(%)	7.4	22.9	19.9	23.5	20.0	23.5	21.4	27.2
EBITDA margin	(%)	15.5	30.6	28.4	30.7	27.1	29.9	27.8	32.6
EBIT margin	(%)	9.0	24.7	22.5	25.4	21.4	24.6	23.0	28.4
Net profit margin	(%)	6.3	19.0	17.2	19.5	15.9	18.3	17.1	26.9
ROE	(%)	48.0	17.3	16.0	18.7	18.0	19.1	21.1	25.5
ROA	(%)	28.8	11.4	10.3	10.9	10.7	12.2	13.1	15.1
Net D/E	(x)	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.5
Interest coverage	(x)	10.7	25.4	22.3	23.3	15.2	15.9	16.0	18.8
Debt service coverage	(x)	0.5	1.6	1.8	1.6	1.1	1.9	1.6	2.4

Main Assumptions									
FY December 31	Unit	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24
Revenue breakdown									
Self-pay service	(%)	54.6	54.7	53.4	56.0	56.1	52.9	48.9	48.4
Social security service (SC)	(%)	47.8	43.9	47.5	43.3	43.8	46.7	50.6	51.5
Other revenues	(%)	(2.4)	1.4	(0.9)	0.7	0.1	0.4	0.5	0.0

### Rajthanee Hospital PLC

### Figure 1: RJH earnings review



(Bt mn)	3Q23	4Q23	1Q24	2Q24	3Q24	ΥοΥ%	QoQ%	9M23	9M24	ΥοΥ%
Revenue	620	623	632	695	794	28.1	14.2	1,725	2,121	23.0
Gross profit	199	199	204	232	306	53.9	32.3	532	742	39.6
EBITDA	194	171	191	196	262	35.2	33.4	527	649	23.2
Core profit	121	99	116	133	214	77.3	60.3	321	463	44.3
Net profit	121	99	116	119	214	77.3	80.2	321	448	39.7
EPS (Bt/share)	0.40	0.33	0.39	0.45	0.71	77.3	60.3	1.07	1.55	44.3
Balance Sheet										
Total Assets	3,831	4,020	3,944	4,154	4,339	13.3	4.5	3,831	4,339	13.3
Total Liabilities	1,515	1,684	1,545	1,718	1,819	20.1	5.9	1,515	1,819	20.1
Total Equity	2,317	2,336	2,399	2,436	2,520	8.8	3.5	2,317	2,520	8.8
BVPS (Bt/share)	6.94	6.83	7.04	7.17	7.41	6.8	3.3	6.94	7.41	6.8
Financial Ratio										
Gross Margin (%)	32.1	31.9	32.3	33.3	38.6	6.5	5.3	30.8	35.0	4.2
EBITDA margin (%)	30.7	27.1	29.9	27.8	32.6	2.0	4.8	30.5	30.6	0.1
Net Profit Margin (%)	19.5	15.9	18.3	17.1	26.9	7.5	9.9	18.6	21.1	2.5
ROA (%)	12.3	10.1	12.2	14.0	20.9			10.9	15.1	
ROE (%)	21.1	17.0	19.1	22.6	35.3			18.7	25.5	
Debt to equity (X)	0.5	0.5	0.5	0.5	0.5			0.5	0.5	
<u>Revenue breakdown</u>										
Self-pay: OPD	169	182	172	163	186	9.9	13.9	478	521	9.1
Self-pay: IPD	177	167	163	177	198	11.8	12.2	289	340	17.4
SC	268	273	295	351	409	52.5	16.4	505	647	28.
Other revenues	5	1	3	3	0	N.M.	N.M.	3	6	110.8

Source: Company data, InnovestX Research

### Figure 2: Valuation summary (price as of Nov 11, 2024)

	Rating	Price	Target	ETR	P/E (x)		EPS gr	owth	(%)	P/	BV (x	:)	RC	<b>)E (</b> %	)	Div.	Yield	(%)	EV/EBITDA (x)			
		(Bt/Sh)	(Bt/Sh)	(%)	23A	24F	25F	23A	24F	25F	23A	24F	25F	23A	24F	25F	23A	24F	25F	23A	24F	25F
BCH	Outperform	16.40	21.0	30.2	27.4	27.1	22.8	(63.0)	1.3	18.7	3.2	3.1	3.0	11	11	12	2.1	2.2	2.7	13.8	13.6	11.5
BDMS	Outperform	26.50	36.0	38.8	29.3	26.0	24.1	14.0	12.6	8.0	4.4	4.3	4.1	15	16	17	2.6	3.0	3.2	17.3	15.7	14.6
BH	Neutral	225.00	300.0	35.5	25.9	23.0	21.9	40.0	12.2	5.0	7.5	6.4	5.6	31	30	27	2.0	2.2	2.3	18.1	15.1	14.1
CHG	Neutral	2.86	2.9	3.8	28.8	28.1	24.6	(60.7)	2.6	13.9	4.2	4.0	3.8	14	14	15	2.4	2.4	2.8	16.8	16.0	14.0
RJH	Neutral	22.70	29.0	34.6	16.2	12.1	12.8	(59.3)	34.1	(5.7)	3.3	3.0	3.0	18	23	21	5.3	6.8	6.6	11.1	9.5	9.3
Average					25.5	23.3	21.3	(25.8)	12.6	8.0	4.8	4.4	4.1	18	18	18	2.3	2.4	2.8	16.5	15.1	13.6

Source: InnovestX Research



### Disclaimer

The information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.

InnovestX Securities Company Limited ("INVX") is wholly owned by SCB X Public Company Limited ("SCBX") and The Siam Commercial Bank Public Company Limited ("SCB") is majority-owned by SCBX. Any information related to SCB is for sector comparison purpose.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly owned by SCB X Public Company Limited ("SCBX"). The Siam Commercial Bank Public Company Limited, which is majority-owned by SCBX, acts as financial advisor of the LH Hotel Leasehold Real Estate Investment Trust. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

INVX reserves the right to modify the Information from time to time without notice and in its sole discretion. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

Futures and Options trading carry a high level of risk with the potential for substantial losses, and are not suitable for all persons. Before deciding to trade Futures and Options, you should carefully consider your financial position, investment objectives, level of experience, and risk appetite if Futures and Options trading are appropriate. The possibility exists that you could sustain a loss of some or all of your initial investment. You should be aware of all the risks associated with Futures and Options trading, and you are advised to rely on your own judgment while making investment decision and/or should seek advice from professional investment advisor if you have any doubts.

This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

© Copyright 2022 InnovestX Securities Co., Ltd. All right reserved.



### CG Rating 2024 Companies with CG Rating

### **Companies with Excellent CG Scoring**

AAV, ABM, ACE, ACG, ADVANC, AE, AF, AGE, AH, AIT, AJ, AKP, AKR, ALLA, ALT, AMA, AMARIN, AMATA, AMATAV, ANAN, AOT, AP, ASIMAR, ASK, ASP, ASW, AURA, AWC, B, BAFS, BAM, BANPU, BAY, BBGI, BBL, BCH, BCP, BCPG, BDMS, BEC, BEM, BEYOND, BGC, BGRIM, BJC, BKIH, BLA, BPP, BR, BRI, BRR, BSRC, BTG, BTS, BTW, BWG, CBG, CENTEL, CFRESH, CHASE, CHEWA, CHOW, CIMBT, CIVIL, CK, CKP, CNT, COLOR, COM7, CPALL, CPAXT, CPF, CPL, CPN, CPW, CRC, CRD, CREDIT, CSC, CV, DCC, DDD, DELTA, DEMCO, DITTO, DMT, DOHOME, DRT, DUSIT, EASTW, ECF, ECL, EGCO, EPG, ERW, ETC, ETE, FLOYD, FN, FPI, FVC, GABLE, GC, GCAP, GFC, GFPT, GGC, GLAND, GLOBAL, GPSC, GRAMMY, GULF, GUNKUL, HANA, HARN, HENG, HMPRO, HPT, HTC, ICC, ICHI, III, ILINK, ILM, IND, INET, INSET, INTUCH, IP, IRC, IRPC, IT, ITC, ITEL, ITTHI, IVL, JAS, JTS, K, KBANK, KCC, KCE, KCG, KEX, KKP, KSL, KTB, KTC, KTMS, KUMWEL, LALIN, LANNA, LH, LHFG, LIT, LOXLEY, LPN, LRH, LST, M, MAJOR, MALEE, MBK, MC, M-CHAI, MCOT, MFC, MFEC, MINT, MODERN, MONO, MOONG, MOSHI, MSC, MST, MTC, MTI, MVP, NCH, NER, NKI, NOBLE, NRF, NSL, NTSC, NVD, NWR, NYT, OCC, OR, ORI, OSP, PAP, PB, PCC, PCSGH, PDJ, PEER, PG, PHOL, PIMO, PLANB, PLAT, PLUS, PM, PORT, PPP, PPS, PR9, PRG, PRIME, PRM, PRTR, PSL, PTT, PTTEP, PTTGC, Q-CON, QH, QTC, RATCH, RBF, RPC, RPH, RS, RT, RWI, S, S&J, SA, SAAM, SABINA, SAK, SAMART, SAMTEL, SAT, SAV, SAWAD, SC, SCAP, SCB, SCC, SCCC, SCG, SCGD, SCGP, SCM, SCN, SDC, SEAFCO, SEAOIL, SELIC, SENA, SENX, SGC, SGF, SGP, SHR, SICT, SIRI, SIS, SITHAI, SJWD, SKE, SKR, SM, SMPC, SNC, SNNP, SNP, SO, SONIC, SPALI, SPC, SPI, SPRC, SR, SSC, SSF, SSP, SSSC, STA, STEC, STGT, STI, SUC, SUN, SUTHA, SVI, SYMC, SYNEX, SYNEC, TASCO, TBN, TCAP, TCMC, TEAMG, TEGH, TFG, TFMAMA, TGE, TGH, THANA, THANI, THCOM, THG\*, THIP, THRE, THREL, TIPH, TISCO, TK, TKS, TKT, TLI, TM, TMILL, TMT, TNDT, TNITY, TNL, TOA, TOG, TOP, TPAC, TPBI, TPIPL, TPIPP, TPS, TQM, TQR, TRP, TRUBB, TRUE, TRV, TSC, TSTE, TSTH, TTA, TTB, TTCL, TTW, TU, TVDH, TVO, TVT, TWPC, UAC, UBE, UBIS, UKEM, UPF, UPOIC, UV, VARO, VGI, VIH, WACOAL, WGE, WHA, WHAUP, WICE, WINMED, WINNER, ZEN

#### **Companies with Very Good CG Scoring**

25, AAI, ADB, AEONTS, AHC, AIRA, APCO, APCS, APURE, ARIP, ARROW, ASIAN, ATP30, AUCT, AYUD, BA, BBIK, BC, BE8, BH, BIZ, BOL, BSBM, BTC, CH, CI, CIG, CM, COCOCO, COMAN, CPI, CSS, DTCENT, EVER, FE, FORTH, FSMART, FSX, FTI, GEL, GIFT, GPI, HUMAN, IFS, INSURE, JCK, JDF, JMART, KGI, KJL, KTIS, KUN, L&E, LHK, MATCH, MBAX, MEGA, METCO, MICRO, NC, NCAP, NCL, NDR, ONEE, PATO, PDG, PJW, POLY, PQS, PREB, PROUD, PSG, PSP, PSTC, PT, PTECH, PYLON, QLT, RABBIT, RCL, SAPPE, SECURE, SFLEX, SFT, SINO, SMT, SPCG, SPVI, STANLY, STPI, SUPER, SUSCO, SVOA, SVT, TACC, TAE, TCC, TEKA, TFM, TITLE, TKN, TMD, TNR, TPA, TPCH, TPCS, TPLAS, TPOLY, TRT, TURTLE, TVH, UBA, UP, UREKA, VCOM, VIBHA, VRANDA, WARRIX, WIN, WP

### **Companies with Good CG Scoring**

A5, ADD, AIE, ALUCON, AMC, AMR, ARIN, ASEFA, ASIA, ASN, BIG, BIOTEC, BIS, BJCHI, BLC, BVG, CEN, CGH, CHARAN, CHAYO, CHIC, CHOTI, CITY, CMC, CPANEL, CSP, DEXON, DOD, DPAINT, DV8, EASON, EE, EFORL, EKH, ESTAR, ETL, FNS, GBX, GENCO, GTB, GYT, ICN, IIG, IMH, IRCP, J, JCKH, JMT, JPARK, JR, JSP, JUBILE, KBS, KCAR, KIAT, KISS, KK, KWC, LDC, LEO, MCA, META, MGC, MITSIB, MK, NAM, NOVA, NTV, NV, OGC, PACO, PANEL, PHG, PIN, PRAPAT, PRI, PRIN, PROEN, PROS, PTC, READY, ROCTEC, SABUY, SALEE, SAMCO, SANKO, SCI, SE, SE-ED, SINGER, SISB, SKN, SKY, SMD, SMIT, SORKON, SPG, SST, STC, STOWER, STP, SVR, SWC, TAKUNI, TC, TFI, TMC, TMI, TNP, TOPP, TRU, UEC, UOBKH, VL, WAVE, WFX, WIIK, XO, XPG, YUASA, ZAA

### **Corporate Governance Report**

The material contained in this publication is for general information only and is not intended as advice on any of the matters discussed herein. Readers and others should perform their own independent analysis as to the accuracy or completeness or legality of such information. The Thai Institute of Directors, its officers, the authors and editor make no representation or warranty as to the accuracy, completeness or legality of any of the information contained herein. By accepting this document, each recipient agrees that the Thai Institute of Directors Association, its officers, the authors and editor shall not have any liability for any information contained in, or for any omission from, this publication. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. InnovestX Securities Company Limited does not conform nor certify the accuracy of such survey result.

To recognize well performers, the list of companies attaining "Good", "Very Good" and "Excellent" levels of recognition (Not including listed companies qualified in the "no announcement of the results" clause from 1 January 2023 to 28 October 2024) is publicized.

\*บริษัทหรือกรรมการหรือผู้บริหารของบริษัทที่มีข่าวด้านการกำกับดูแลกิจการ เช่น การกระทำผิดเกี่ยวกับหลักทรัพย์ การทุจริต คอร์รัปชัน เป็นต้น ซึ่งการใช้ข้อมูล CGR ควรตระหนักถึงข่าวดังกล่าว ประกอบด้วย

#### Anti-corruption Progress Indicator

### Certified (ได้รับการรับรอง)

2S, AAI, ADB, ADVANC, AE, AF, AH, AI, AIE, AIRA, AJ, AKP, AMA, AMANAH, AMATA, AMATAV, AP, APCS, AS, ASIAN, ASK, ASP, ASW, AWC, AYUD, B, BAFS, BAM, BANPU, BAY, BBGI, BBL, BCH, BCP, BCPG, BE8, BEC, BEYOND, BGC, BGRIM, BLA, BPP, BRI, BRR, BSBM, BTG, BTS, BWG, CAZ, CBG, CEN, CENTEL, CFRESH, CGH, CHEWA, CHOTI, CHOW, CI, CIG, CIMBT, CM, CMC, COM7, CPALL, CPAXT, CPF, CPI, CPL, CPN, CPW, CRC, CSC, CV, DCC, DELTA, DEMCO, DIMET, DMT, DOHOME, DRT, DUSIT, EA, EASTW, ECF, EGCO, EP, EPG, ERW, ETC, ETE, FNS, FPI, FFT, FSMART, FSX, FTE, GBX, GC, GCAP, GEL, GFPT, GGC, GJS, GLOBAL, GPI, GPSC, GSTEEL, GULF, GUNKUL, HANA, HARN, HEALTH, HENG, HMPRO, HTC, ICC, ICHI, IFS, III, ILINK, ILM, INET, INOX, INSURE, INTUCH, IRPC, ITEL, IVL, JAS, JR, JTS, KASET, KBANK, KCAR, KCC, KCE, KGEN, KGI, KKP, KSL, KTB, KTC, L&E, LANNA, LH, LHFG, LHK, LPN, LRH, M, MAJOR, MALEE, MATCH, MBAX, MBK, MC, MCOT, MEGA, MENA, META, MFC, MFEC, MILL, MINT, MODERN, MONO, MOONG, MSC, MTC, MTI, NATION, NCAP, NEP, NER, NKI, NOBLE, NRF, OCC, OGC, OR, ORI, OSP, PAP, PATO, PB, PCSGH, PDG, PDJ, PG, PHOL, PIMO, PK, PL, PLANB, PLANET, PLAT, PM, PPP, PPPM, PPS, PR9, PREB, PRG, PRINC, PRM, PROS, PRTR, PSH, PSL, PSTC, PT, PTECH, PTG, PTT, PTTEP, PTTGC, PYLON, Q-CON, QH, QLT, QTC, RABBIT, RATCH, RBF, RML, RS, RWI, S&J, SA, SAAM, SABINA, SAK, SAPPE, SAT, SC, SCB, SCC, SCC, SCG, SCGP, SCM, SCN, SEAOIL, SE-ED, SELIC, SENA, SENX, SFLEX, SGC, SGP, SIRI, SIS, SITHAI, SKR, SM, SMIT, SMPC, SNC, SNP, SORKON, SPACK, SPALI, SPC, SPI, SPRC, SRICHA, SSF, SSP, SSSC, SST, STA, STGT, STOWER, SUSCO, SVI, SVOA, SVT, SYMC, SYNTEC, TAE, TAKUNI, TASCO, TCAP, TEGH, TFG, TFI, TFMAMA, TGE, TGH, THANI, THCOM, THIP, THRE, THREL, TIDLOR, TIPCO, TIPH, TISCO, TKN, TKS, TKT, TMD, TMILL, TMT, TNITY, TNL, TNP, TNR, TOG, TOPP, TPA, TPCS, TPLAS, TRT, TRU, TRUE, TSC, TSI, TSTE, TSTH, TTB, TTCL, TU, TURTLE, TVDH, TVO, TWPC, UBIS, UEC, UKEM, UPF, UV, VCOM, VGI, VIBHA, VIH, WACOAL, WHA, WHAUP, WICE, WIIK, WPH, XO, YUASA, ZEN Declared (ประกาศเจตนารมณ์)

ACE, ALT, AMARIN, AMC, ANI, APCO, ASAP, B52, BLAND, BYD, CFARM, CHASE, CHG, DEXON, DITTO, ECL, EVER, FLOYD, GREEN, HL, HUMAN, ICN, IHL, IP, ITC, JDF, JMART, K, KJL, LDC, LIT, MITSIB, MJD, MOSHI, NEX, NTSC, PLE, PLUS, POLY, PQS, PRI, PRIME, PROEN, PROUD, PTC, RT, S, SAWAD, SCAP, SCGD, SFT, SHR, SINGER, SINO, SJWD, SKE, SNNP, SOLAR, SONIC, SUPER, TBN, TMI, TPAC, TPP, TOM, UOBKH, UREKA, VNG, WELL, WIN, XPG

### N/A

24CS, 3K-BAT, A, A5, AAV, ABM, ACAP, ACC, ACG, ADD, ADVICE, AEONTS, AFC, AGE, AHC, AIT, AJA, AKR, AKS, ALLA, ALPHAX, ALUCON, AMARC, AMR, ANAN, AOT, APO, APP, APURE, AQUA, ARIN, ARIP, ARROW, ASEFA, ASIA, ASIMAR, ASN, ATP30, AU, AUCT, AURA, BA, BBIK, BC, BCT, BDMS, BEAUTY, BEM, BGT, BH, BIG, BIOTEC, BIS, BIZ, BJCH, BKD, BKGI, BKIH, BLC, BLESS, BLISS, BM, BOL, BPS, BR, BROCK, BSM, BSRC, BTC, BTNC, BTW, BUI, BVG, CCET, CCP, CEYE, CGD, CH, CHAO, CHARAN, CHAYO, CHIC, CHO, CITY, CIVIL, CK, CKP, CMAN, CMO, CMR, CNT, COCOCO, COLOR, COMAN, CPANEL, CPH, CPR, CPT, CRANE, CRD, CREDIT, CSP, CSR, CSS, CTW, CWT, D, DCON, DDD, DHOUSE, DOD, DPAINT, DTCENT, DTCI, DV8, EASON, EE, EFORL, EKH, EMC, ESTAR, ETL, EURO, F&D, FANCY, FE, FM, FMT, FN, FORTH, FTI, FVC, GABLE, GENCO, GFC, GIFT, GL, GLAND, GLOCON, GLORY, GRAMMY, GRAND, GSC, GTB, GTV, GYT, HFT, HPT, HTECH, HYDRO, 12, IIG, IMH, IND, INGRS, INSET, IRC, IRCP, IROYAL, IT, ITD, ITNS, ITTHI, J, JAK, JCK, JCKH, JCT, JKN, JMT, JPARK, JSP, JUBILE, KAMART, KBS, KC, KCG, KCM, KDH, KEX, KIAT, KISS, KK, KKC, KLINIQ, KOOL, KTIS, KTMS, KUMWEL, KUN, KWC, KWI, KWM, KYE, LALIN, LEE, LEO, LOXLEY, LPH, LST, LTS, MAGURO, MANRIN, MASTER, MATI, MCA, M-CHAI, MCS, MDX, MEB, MEDEZE, METCO, MGC, MGI, MGT, MICRO, MIDA, MK, ML, MORE, MPJ, MST, MTW, MUD, MVP, NAM, NAT, NC, NCH, NCL, NCP, NDR, NEO, NETBAY, NEW, NEWS, NFC, NL, NNCL, NOK, NOVA, NPK, NSL, NTV, NUSA, NV, NVD, NWR, NYT, OHTL, OKJ, ONEE, ORN, PACO, PAF, PANEL, PCC, PCE, PEACE, PEER, PERM, PF, PHG, PICO, PIN, PJW, PLT, PMC, PMTA, POLAR, PORT, PPM, PRAKIT, PRAPAT, PRECHA, PRIN, PRO, PSG, PSP, PTL, QTCG, RAM, RCL, READY, RICHY, RJH, ROCK, ROCTEC, ROH, ROJNA, RP, RPC, RPH, RSP, S11, SABUY, SAF, SAFARI, SAFE, SALEE, SAM, SAMART, SAMCO, SAMTEL, SANKO, SAUCE, SAV, SAWANG, SBNEXT, SCI, SCL, SCP, SDC, SE, SEAFCO, SECURE, SEI, SGF, SHANG, SIAM, SICT, SIMAT, SISB, SK, SKN, SKY, SLP, SMART, SMD, SMT, SO, SPA, SPCG, SPG, SPREME, SPVI, SQ, SR, SRS, SSC, STANLY, STC, STECH, STECON, STHAI, STI, STP, STPI, STX, SUC, SUN, SUTHA, SVR, SWC, SYNEX, TACC, TAN, TAPAC, TATG, TC, TCC, TCJ, TCMC, TCOAT, TEAM, TEAMG, TEKA, TERA, TFM, TGPRO, TH, THAI, THANA, THE, THG, THMUI, TIGER, TITLE, TK, TKC, TLI, TM, TMAN, TMC, TMW, TNDT, TNH, TNPC, TOA, TPBI, TPCH, TPIPL, TPIPP, TPL, TPOLY, TPS, TQR, TR, TRC, TRITN, TRP, TRUBB, TRV, TSE, TTA, TTI, TTT, TTW, TVH, TVT, TWP, TWZ, TYCN, UAC, UBA, UBE, UMI, UMS, UNIQ, UP, UPOIC, UTP, UVAN, VARO, VL, VPO, VRANDA, W, WARRIX, WAVE, WFX, WGE, WINDOW, WINMED, WINNER, WORK, WP, YGG, YONG, ZAA, ZIGA

#### Explanations

Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of October 14, 2024) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.